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Summary 
The diagnosis and treatment of breast cancer has rapidly evolved over the past 20 
years. Starting in the 1980s, there have been important alterations in the diagnosis and 
treatment of breast cancer, having an important impact on the diagnostic procedure 
employed by pathologists. Numerous studies in recent years have identified many pro-
gnostic and predictive factors for breast cancer. Most of them have been determined 
pathohistologically, which resulted in a large responsibility for pathologists, therefore 
the pathologist has become a key person in a multidisciplinaty team of breast cancer 
and the person very responsible for the implementation of specific individual therapy.
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Breast cancer is the most common cancer among women in both deve-
loping and developed regions in the world. Clinical cancer develops over 
a long period of time, requires multiple molecular alterations, and involves 
evolution of cellular populations with increasingly aggressive phenotypic 
characteristics [1]. Although the time required for the process of carcino-
genesis is not well established for any human cancer, estimate suggest that 
this multistep process unfolds over many years and possibly several deca-
des. Breast cancer represents a diverse collection of malignant diseases of 
the breast with highly variable clinical behaviors and disparate response to 
therapy [2]. 
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Personalised oncology is evidence-based, individualised medicine that 
delivers the right care to the right cancer patient at the right time and results 
in measurable improvements in outcomes and a reduction on health care 
costs. The essence of personalised oncology lies in the use of biomarkers. The 
biomarkers can be from tissue, serum,urin or imaging and must be valida-
ted. Also, their have different importances: predictive, prognostic and early 
response biomarkers.
The diagnosis and treatment of breast cancer has rapidly evolved over the 
past 20 years. In the first part of the 20th century, treatment of breast cancer 
consisted of radical mastectomy, but adjuvant systemic treatment and adju-
vant radiotherapy did not play a major role. Diagnosis of breast cancer was 
mostly made based on clinical presentation, later aided by mammography 
and often combined with frozen section pathology confirmation. Starting in 
the 1980s, there have been important alterations in the diagnosis and tre-
atment of breast cancer, having an important impact on the diagnostic pro-
cedure employed by pathologists.
Histopathological features play an important role in guiding the tre-
atment decisions. In addition, genetic research is starting to have an incre-
asing impact on guiding therapy by providing prognostic and predictive 
factors [3]. 
To obtain optimal morphology in  the histology sections, and to obtain 
optimal immunohistochemical staining results, the resection specimen sho-
uld be cut into thin slices immediately after surgery.
For microscopic examination the pathologist should be obtained and pro-
cessed for paraffin sections full diameter of the tumour and its surroundin-
gs, small part of the tumour to perform immunohistochemistry, if there are 
macroscopical or radiological abnormalities in  the tissue surrounding the 
invasive tumour, these areas should be sampled. If the surrounding tissue 
is without abnormalities, it is necessary to take at least two sections from 
macroscopically normal breast tissue. 
On slides stained with hematoxylin eosin (H.E.), pathologist must deter-
mine the prognostic and predictive factors for breast cancer. This includes 
the histological type of cancer [4], the degree of tumour differentiation [5], 
mitotic counts, lymphovascular invasion, estrogen and progesterone recep-
tors [6], protein HER-2 [7] and proliferative index Ki-67 [8].
Receptors are determined by immunohistochemistry and the results are 
expressed as the percentage of positive cells and intensity of staining. Stai-
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ning for estrogen and progesterone receptor is allways nuclear in localizati-
on and in most institutes all patients with a tumour in which more than 10% 
or more 1% of the tumour cells show positive staining regardless of the in-
tensity of staining are candidates for adjuvant hormonal therapy. According 
to the consensus of the St Gallen 2014. cut-off of the progesterone receptors 
is 20%. This value best separating luminal type A from luminal type B bre-
ast cancer. Values below 20% indicate that the progesterone receptors are 
negative or low [9]. When negative staining for estrogen and/or progestrone 
receptor is seen, it is important to confirm that staining of the hormone re-
ceptor-negative case has been successful. This can usually be tested, since 
the majority of normal breast tissues contain some nuclei ducts and lobules 
that are positive for estrogen and progesterone receptor. If no normal breast 
epithelial cells are found to show positive staining, the hormone receptor 
assays should be repeated on another tumour block.
HER-2 gene amplification is observed in 15-30% of invasive breast cancers 
and leads to HER-2 receptor overexpression. HER-2 positive invasive breast 
cancers respond favourable to therapies that specifically target the HER-2 
protein, therefore it is very important today to identify candidates for this 
type of targeted therapy. Several technologies are available for determining 
HER-2 status, but the two most commonly used are immunohistochemistry 
[IHC], which measures HER-2 protein expression and CISH  [chromogen in 
situ hybridisation] which detects HER-2 gene amplification a method that is 
often used today in the pathology than FISH (fluorescence in situ hybridisati-
on). The interpretation of the results is based on the intensity and percentage 
of stained cells. The most commonly used score system is  0, 1+ (negative re-
sults) , 2+  and 3+ (positive results). A 2+ is considered equivocal and should 
be followed by retesting by CISH. Women with IHC 3+ tumours are candi-
dates for therapy with trastuzumab, but women with 2+ tumour should be 
retested and if the results show  amplification of gene of those are candidates 
for trastuzumab. To ensure the highest possible accuracy, pathology centers 
must standardise methodologies and testing procedures.
Proliferative index is also very important and is determined  by immu-
nohistochemistry by monoclonal antibody  Ki-67. Positive reaction is nuclear 
reaction and are counted positive nuclei in 1000 tumour cells on the high 
magnification and the results obtained is expressed as a percentage of posi-
tive nuclei. According to St Gallen consensus cut of value is 20% of positive 
22
Rad 520. Medical Sciences, 40 (2014) : 19-23
B. Šarčević: The role of the pathologist in the individualisation of therapy in patients with breast cancer
cells, which means that below this value is low and value above 20%  is high 
proliferative indeks [9].
Based on the receptors, HER-2 status and proliferative index breast can-
cers are classified immunophenotypically into five subgroups: luminal type 
A, luminal type B HER-2 negative, luminal type B Her-2 positive, HER-2 po-
sitive (non-luminal type) and triple negative tumours.  Based on the immu-
nophenotype of the cancer patients receive appropriate therapy. The multi-
gene testing remains inaccesible for the majority of women with early breast 
cancer, therefore is adopted clinico-pathological testing, now expressed in 
surrogate IHC-based classification.
Numerous studies in recent years have identified many prognostic and 
predictive factors for breast cancer. Most of them determined pathohistolo-
gically, which resulted in a large responsibility for pathologists. In addition, 
the pathologist has become a key person in a multidisciplinaty team of breast 
cancer and the person very responsible for the implementation of specific 
individual therapy.
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Sažetak
Uloga patologa u individualiziranoj terapiji bolesnica s karcinomom dojke
Unazad 20 godina dijagnostika i liječenje karcinoma dojke snažno je napredovalo. 
Počevši od 1980. godine  kada su počele biti važne promjene u dijagnostici i liječenju 
karcinoma dojke, sve je to utjecalo na dijagnostički postupak i rad patologa. Brojna no-
vija istraživanja utvrdila su većinu prognostičkih i prediktivnih čimbenika za karcinom 
dojke. Većina njih određuje se patohistološki a što je u konačnici rezultiralo velikom 
odgovornošću patologa koji je postao ključna osoba u multidisciplinarnom timu za kar-
cinom dojke i vrlo odgovorna osoba za  primjenu specifične individualizirane terapije.
Ključne riječi: karcinom dojke; patolog; personalizirana terapija.
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